Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Wells defends Immunomedics, 19% selloff a "buying opportunity"

Published 11/13/2017, 03:58 PM
© Reuters.  Wells defends Immunomedics, 19% selloff a "buying opportunity"
WFC
-
IMMU
-
  • Wells Fargo (NYSE:WFC)'s Jim Birchenough says today's negative action for Immunomedics (IMMU -19.1%) is a "buying opportunity" after seeing an overview of abstract data on lead candidate IMMU-132 (sacituzumab govitecan), adding that the results support accelerated approval (OUTPERFORM/$14).
  • Source: Bloomberg
  • Investors appear concerned about the company's lack of disclosure of data to be presented at the San Antonio Breast Cancer Symposium in early December. One abstract (#1727) will detail Phase 2 results in treatment-resistant metastatic triple negative breast cancer. The objective response rate was 34% as determined by local radiologist assessment but the results from the independent central blinded review will be presented at the meeting.
  • Now read: Xencor (XNCR) Presents At Society for Immunotherapy of Cancer - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.